Abstract
Background Vaccines have reduced severe disease and death from COVID-19. However, with evidence of waning efficacy coupled with continued evolution of the virus, health programmes need to evaluate the requirement for regular booster doses, considering their impact and cost-effectiveness in the face of ongoing transmission and substantial infection-induced immunity.
Methods and findings We developed a combined immunological-transmission model parameterised with data on transmissibility, severity, and vaccine effectiveness. We simulated SARS-CoV-2 transmission and vaccine rollout in characteristic global settings with different population age-structures, contact patterns, health system capacities, prior transmission, and vaccine uptake. We quantified the impact of future vaccine booster dose strategies with both original and variant-adapted vaccine products, in the presence of both continuing transmission of Omicron subvariants and considering the potential future emergence of new variants with modified transmission, immune escape, and severity properties. We found that regular boosting of the oldest age group (75+) is the most efficient strategy, although large numbers of hospitalisations and deaths can be averted by extending vaccination to younger age groups. In countries with low vaccine coverage and high infection-derived immunity, boosting older at-risk groups is more effective than continuing primary vaccination into younger ages. These findings hold if even if virus drift results in a gradual reduction in vaccine effectiveness over time due to immune escape. In a worst-case scenario where a new variant emerges that is 10% more transmissible, as severe as Delta, and exhibits substantial further immune escape, demand on health services could be similar to that experienced during 2020.
Conclusions Regular boosting of the high-risk population remains an important tool to reduce morbidity and mortality from current and future SARS-CoV-2 variants. The cost-effectiveness of boosting is difficult to assess given the ongoing uncertainty in the likelihood of future variants and their properties but focusing vaccination in the highest-risk cohorts remains the most efficient strategy to reduce morbidity and mortality.
Competing Interest Statement
ACG is a non-renumerated member of a scientific advisory board for Moderna, has received consultancy funding from GSK for educational activities related to COVID-19 vaccination and is a member of the CEPI scientific advisory board. She has received grant funding from Gavi for COVID-19 related work. ABH, PW and ACG have previously received consultancy payments from WHO for COVID-19 related work. ABH provides COVID-19 modelling advice to the New South Wales Ministry of Health, Australia. ABH was previously engaged by Pfizer Inc to advise on modelling RSV vaccination strategies for which she received no financial compensation. EMR is a non-remunerated member of the UK Vaccines Network, the UKRI COVID-19 taskforce and the British Society for Immunology Covid-19 taskforce.
Funding Statement
This work was supported by a grant from WHO. ABH acknowledges support from an NHMRC Investigator Grant and Imperial College Research Fellowship. PW is supported by an Imperial College Research Fellowship. OJW is supported by a Schmidt Science Fellowship in partnership with the Rhodes Trust. GC and ACG acknowledge support from The Wellcome Trust. ABH, PD, PW, GC, GB, SLW, NMF and ACG acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), funded by the UK Medical Research Council (MRC) and part of the EDCTP2 programme supported by the European Union. This work was additionally supported by the NIHR Health Protection Unit for Modelling and Health Economics (NMF: [NIHR200908]) and philanthropic funding from Community Jameel (PD, NMF). WHO provided feedback and relevant data on early iterations of the scenarios presented here but did not endorse the outputs or play any other role in the study. The other funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval is not required as this is a modelling study using data in the public domain.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The model code is open access at https://mrc-ide.github.io/safir. All analysis code is available at https://github.com/mrc-ide/covid_booster_strategies.
